2022 - How Agile Clinical Trials Unlock Universal Access to Rare Disease Research

Arguably, the greatest challenge in rare disease clinical research is finding enough diagnosed patients who can travel frequently to trial sites. The greatest benefit, however, of a decentralized clinical trial (DCT) is the ability to break down geographical barriers, enabling universal access to all patients and providers. Does this mean, therefore, that DCTs and rare diseases are a match made in heaven?
The agile clinical trial of the future, comprising a bespoke mix of traditional and decentralized components, has the potential to transform and accelerate the development of treatments for rare diseases. Advanced enrollment techniques bring clinical trials to the diagnosed patients who need them most, while also increasing the diversity of study populations. Meanwhile, the replacement of numerous clinic-based activities with home visits and remote digital tools greatly reduces the burden on participants and creates a highly patient-focused environment.
Science 37’s research shows that rare diseases will be among the most prevalent categories for incorporating decentralized approaches into future clinical trial designs.
This webinar will explore some of the key issues, opportunities and best practices around the following topics:
Why the agile clinical trial model is potentially a great fit for many rare disease categories
How agile clinical trials are intrinsically patient-focused, and how to maximize engagement
What successful enrollment looks like for an agile clinical trial in a rare disease category
Navigating the regulatory landscape for agile clinical trials in rare diseases
Designing studies that are safe, appropriate and that generate reliable data
Case studies and appropriate use cases for agile clinical trials in rare disease categories
Join this webinar to learn about accelerating rare disease research with agile clinical trials.